Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Pregabalin for the treatment of patients with generalized anxiety disorder with inadequate treatment response to antidepressants and severe depressive symptoms

Olivares, José M.a; Álvarez, Enriqueb; Carrasco, José L.c; Pérez Páramo, Maríad; López-Gómez, Vanessad

International Clinical Psychopharmacology: September 2015 - Volume 30 - Issue 5 - p 265–271
doi: 10.1097/YIC.0000000000000087

To evaluate the effectiveness of pregabalin in patients with resistant generalized anxiety disorder (GAD) and severe depressive symptoms, we carried out a post-hoc analysis of a multicenter, prospective, and observational 6-month study. We included patients who were at least 18 years old, fulfilled the Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV) criteria for GAD, showed inadequate responses to previous courses of antidepressant treatment, had Montgomery–Asberg Rating Scale scores of at least 35, had not received pregabalin previously, and were prescribed pregabalin upon entry into this study. We included 1815 patients fulfilling the DSM-IV criteria for GAD, and 133 (7.3%) fulfilled the selection criteria for these analyses. Ninety-seven percent of the patients received pregabalin (mean dose: 222 mg/day) in combination with other psychotropics. The Hamilton Anxiety Scale total score was reduced by a mean of 20.3 points (95% confidence interval, 22.1–18.4) (57.2% reduction) at month 6. Pregabalin also ameliorated comorbid depressive symptoms, with a reduction in the mean score of the Montgomery–Asberg Rating Scale of 22.3 points (95% confidence interval, 24.2–20.4) (56.6% reduction). Our results suggest that pregabalin, as part of a combination regimen with antidepressants and/or benzodiazepines, might be effective for the treatment of patients with GAD who have shown inadequate response to previous antidepressants and have severe depressive symptoms.

aDepartment of Psychiatry, Hospital Meixoeiro, Complejo Hospitalario Universitario, Vigo

bDepartment of Psychiatry, Hospital de la Santa Creu i San Pau, Universitat Autónoma de Barcelona, Barcelona

cDepartment of Psychiatry, Hospital Clínico San Carlos, Universidad Complutense de Madrid

dMedical Department, Pfizer GEP SLU, Alcobendas, Madrid, Spain

Correspondence to María Pérez Páramo, PhD, Medical Unit, Pfizer España, Avda. de Europa, 20 B, Parque Empresarial La Moraleja, 28108 Alcobendas, Madrid, Spain Tel: +34 914 909 578; fax: +34 914 909 750; e-mail:

Received January 27, 2015

Accepted May 19, 2015

Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.